(R)-3-methyl-2-(((4-(pentan-3-yl)furan-2-yl)methylene)amino)butan-1-ol | 946113-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (R)-3-methyl-2-(((4-(pentan-3-yl)furan-2-yl)methylene)amino)butan-1-ol
• CAS: 946113-03-7
• 化学式: C₁₅H₂₅NO₂
• 分子量: 251.369
• InChiKey: VEYOUHQIPPQQMC-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.62
• 重原子数：
  18.0
• 可旋转键数：
  7.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  45.73
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (R)-3-methyl-2-(((4-(pentan-3-yl)furan-2-yl)methylene)amino)butan-1-ol 在 三乙胺 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 生成 (R)-3-(3,4-dioxo-2-(1-(4-(pentan-3-yl)furan-2-yl)propylamino)cyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide
  参考文献：
  名称：

  C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

  摘要：

  A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCRI Ki = 3 nM, IC50= 7.3 nM), and demonstrates potent inhibition against both Gro-alpha and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50=0.5nM,CXCRI IC50= 37 nN1). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.016
• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 、 magnesium sulfate 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 (R)-3-methyl-2-(((4-(pentan-3-yl)furan-2-yl)methylene)amino)butan-1-ol
  参考文献：
  名称：

  C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

  摘要：

  A novel series of cyclobutenedione centered C(4)-alkyl substituted furanyl analogs was developed as potent CXCR2 and CXCR1 antagonists. Compound 16 exhibits potent inhibitory activities against IL-8 binding to the receptors (CXCR2 Ki = 1 nM, IC50 = 1.3 nM; CXCRI Ki = 3 nM, IC50= 7.3 nM), and demonstrates potent inhibition against both Gro-alpha and IL-8 induced hPMN migration (chemotaxis: CXCR2 IC50=0.5nM,CXCRI IC50= 37 nN1). In addition, 16 has shown good oral pharmacokinetic profiles in rat, mouse, monkey, and dog. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.016